This phase IIb IV-oral step-down study of SCY-078 in patients with in patients with invasive candidiasis

Trial Profile

This phase IIb IV-oral step-down study of SCY-078 in patients with in patients with invasive candidiasis

Planning
Phase of Trial: Phase II

Latest Information Update: 08 May 2018

At a glance

  • Drugs Ibrexafungerp (Primary) ; Ibrexafungerp (Primary)
  • Indications Candidiasis
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 May 2018 According to a Scynexis media release, this trial is expected to begin in the fourth quarter of 2018.
    • 08 May 2017 According to a Scynexis media release, this trial is expected to begin in 2018.
    • 10 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top